The reported results are promising: Over 80% relative bioavailability Around 160 higher bioavailability vs oral tablets Sustained drug levels for ~1 week (once-weekly dosing potential) Additionally, the microneedle patches are stable at room temperature, eliminating the need for cold storage, unlike semaglutide injections
Over time, the brain unlearns the pull toward alcohol
10 The GI side effects of GLP-1 receptor agonists are common, but these symptoms commonly decrease with continued use due to tachyphylaxis
The FDA reclassified it as a biologic a few years ago, and it effectively disappeared from compounding availability overnight
Conclusion GLP-1 receptor agonists represent a significant advancement in managing pediatric diabetes and obesity, providing options that directly address insulin resistance, promote weight loss and reduce risks from related comorbidities
The buzz is there, but so are the questions